Summary
Amgen Inc. announced on May 7, 2002, a significant strategic acquisition that will expand its European market presence for its key oncology products, Filgrastim and pegfilgrastim. The company purchased the rights, assets, and business related to these drugs from F. Hoffman-La Roche Ltd. for $137.5 million. This transaction, effective January 1, 2002, for the European Union, Switzerland, and Norway, aims to consolidate Amgen's control over these important therapies in major European markets. While Amgen gains direct control over these lucrative territories, Roche will retain licensing rights for Filgrastim and pegfilgrastim in other regions, including Eastern Europe, the Middle East, Africa, Asia, and Latin America. This move is likely intended to streamline Amgen's commercial operations and potentially enhance its ability to leverage these products more effectively across the core European Union market, which represents a substantial opportunity for growth in the oncology sector.
Key Highlights
- 1Amgen Inc. acquired rights to Filgrastim and pegfilgrastim in the EU, Switzerland, and Norway from Roche for $137.5 million.
- 2The transaction's effective date for the EU is January 1, 2002.
- 3Roche will continue to hold licensing rights for these products in various other global regions (Eastern Europe, Middle East, Africa, Asia, Latin America).
- 4The acquisition strengthens Amgen's commercial control over key oncology products in major European markets.
- 5This strategic move indicates Amgen's focus on expanding its European footprint.
- 6The press release announcing the transaction is attached as Exhibit 99.1.